BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 22805146)

  • 1. Basal cell carcinoma rebound after cessation of vismodegib in a nevoid basal cell carcinoma syndrome patient.
    Wolfe CM; Green WH; Cognetta AB; Hatfield HK
    Dermatol Surg; 2012 Nov; 38(11):1863-6. PubMed ID: 22805146
    [No Abstract]   [Full Text] [Related]  

  • 2. Vismodegib (Erivedge) for basal cell carcinoma.
    Med Lett Drugs Ther; 2012 Jul; 54(1394):53-4. PubMed ID: 22777303
    [No Abstract]   [Full Text] [Related]  

  • 3. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome.
    Tang JY; Mackay-Wiggan JM; Aszterbaum M; Yauch RL; Lindgren J; Chang K; Coppola C; Chanana AM; Marji J; Bickers DR; Epstein EH
    N Engl J Med; 2012 Jun; 366(23):2180-8. PubMed ID: 22670904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vismodegib in advanced basal-cell carcinoma.
    Henkin RI
    N Engl J Med; 2012 Sep; 367(10):970; author reply 970-1. PubMed ID: 22931271
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of Calcium Channel Blockade on Vismodegib-Induced Muscle Cramps.
    Ally MS; Tang JY; Lindgren J; Acosta-Raphael M; Rezaee M; Chanana AM; Epstein EH
    JAMA Dermatol; 2015 Oct; 151(10):1132-4. PubMed ID: 26200175
    [No Abstract]   [Full Text] [Related]  

  • 6. 9q22.3 Microdeletion Syndrome with Multiple Basal Cell Carcinomas Treated with Vismodegib: Three Key Messages in One Patient.
    Kieny A; Kremer V; Scheidecker S; Lipsker D
    Acta Derm Venereol; 2018 Feb; 98(2):287-288. PubMed ID: 29057423
    [No Abstract]   [Full Text] [Related]  

  • 7. Comment on basal cell carcinoma rebound after cessation of vismodegib in an individual with basal cell nevus syndrome.
    Ally MS; Wysong A; Tang JY; Aasi S
    Dermatol Surg; 2013 Sep; 39(9):1413-4. PubMed ID: 23682843
    [No Abstract]   [Full Text] [Related]  

  • 8. Targeting the hedgehog pathway to treat basal cell carcinoma.
    Geeraert P; Williams JS; Brownell I
    J Drugs Dermatol; 2013 May; 12(5):519-23. PubMed ID: 23652945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral hedgehog-pathway inhibitors for basal-cell carcinoma.
    Lear JT
    N Engl J Med; 2012 Jun; 366(23):2225-6. PubMed ID: 22670909
    [No Abstract]   [Full Text] [Related]  

  • 10. [Vismodegib in metastasized basal cell carcinoma].
    Reinders MG; Dirix L; Mosterd K; van Doorn R
    Ned Tijdschr Geneeskd; 2013; 157(12):A6011. PubMed ID: 23515044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.
    Cirrone F; Harris CS
    Clin Ther; 2012 Oct; 34(10):2039-50. PubMed ID: 23036338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intermittent Vismodegib Therapy in Basal Cell Nevus Syndrome.
    Yang X; Dinehart SM
    JAMA Dermatol; 2016 Feb; 152(2):223-4. PubMed ID: 26509945
    [No Abstract]   [Full Text] [Related]  

  • 13. Histologic changes in basal cell carcinoma after treatment with vismodegib.
    Aldabagh B; Yu J; Perkocha LA; Arron S
    Dermatol Surg; 2013 Nov; 39(11):1703-5. PubMed ID: 23879864
    [No Abstract]   [Full Text] [Related]  

  • 14. Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Tang JY; Ally MS; Chanana AM; Mackay-Wiggan JM; Aszterbaum M; Lindgren JA; Ulerio G; Rezaee MR; Gildengorin G; Marji J; Clark C; Bickers DR; Epstein EH
    Lancet Oncol; 2016 Dec; 17(12):1720-1731. PubMed ID: 27838224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Four-year experience with vismodegib hedgehog inhibitor therapy.
    Simone PD; Schwarz JM; Strasswimmer JM
    J Am Acad Dermatol; 2016 Jun; 74(6):1264-5. PubMed ID: 27185433
    [No Abstract]   [Full Text] [Related]  

  • 16. Enlarging Multiple Neoplastic Skin Growths.
    Feinstein EG; Zhou M; Setabutr P
    JAMA Ophthalmol; 2016 Mar; 134(3):337-8. PubMed ID: 26767432
    [No Abstract]   [Full Text] [Related]  

  • 17. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.
    Lyseng-Williamson KA; Keating GM
    Am J Clin Dermatol; 2013 Feb; 14(1):61-4. PubMed ID: 23329081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surgical excision after neoadjuvant therapy with vismodegib for a locally advanced basal cell carcinoma and resistant basal carcinomas in Gorlin syndrome.
    Chang AL; Atwood SX; Tartar DM; Oro AE
    JAMA Dermatol; 2013 May; 149(5):639-41. PubMed ID: 23677114
    [No Abstract]   [Full Text] [Related]  

  • 19. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
    Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
    J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
    Proctor AE; Thompson LA; O'Bryant CL
    Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.